Growing Demand for Inflammatory Heart Disease Treatment Drives the Market

Global inflammatory heart disease diagnosis and treatment market is anticipated to grow at a CAGR of 8.4% during the forecast period (2024–2031). The increasing prevalence of inflammatory heart disease due to changing lifestyles and heightened awareness of early diagnosis and treatment of diseases is promoting market growth. Moreover, there is a significant increase in demand for advanced diagnostic and therapeutic procedures, these factors collectively drive the market growth. 

Browse the full report description of “Inflammatory Heart Disease Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Type (Endocarditis, Myocarditis, and Pericarditis), by Diagnosis (Imaging Tests, Laboratory Tests, Electrocardiography (ECG or EKG), Biopsy, and Others) and by Treatment (Medications, and Surgical Procedure) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/inflammatory-heart-disease-market

Recent Developments

• In April 2024, BIOTRONIK received CE approval and completed the first European implantation of its newest Insertable Cardiac Monitor (ICM), the BIOMONITOR IV. This device utilizes artificial intelligence to minimize false positives and uniquely offers discrimination capabilities for premature ventricular and atrial contractions (PVC and PAC). It ensures superior signal quality and dependable transmission for effective remote patient management.

• In January 2024, Occlutech, a Swedish medical device company focusing on structural heart disease, obtained FDA approval for its ASD Occluder treating atrial septal defects (ASDs). The FDA has also approved its Pistol Pusher delivery system. These products will be distributed exclusively in the US through a partnership with B. Braun Interventional Systems. 

• In December 2022, Abbott launched the Transcatheter Aortic Valve Implementation (TAVI) system, making it available for people in India with aortic stenosis having high surgical risk. 

Market Coverage  

· The market number available for 2023-2031 

· Base year: 2023 

· Forecast period: 2024-2031 

· Segment Covered- 

o By Type

o By Treatment

o By Diagnostic Test

· Regions Covered- 

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World

• Competitive Landscape: Abbott Laboratories, Novartis Pharma AG, Johnson & Johnson Services, Inc., Pfizer Inc., and Siemens Healthcare Pvt. Ltd. among others.

Key questions addressed by the report 

• What is the market's growth rate? 
• Which segment and region dominate the market in the base year? 
• Which segment and region will project the fastest growth in the market? 
• Who is the leader in the market? 
• How are players addressing challenges to sustain growth? 
• Where is the investment opportunity? 

Global Inflammatory Heart Disease Diagnosis and Treatment Market Report Segment 

By Type

• Atherosclerosis
• Myocarditis
• Pericarditis

By Diagnostic Test

• Electrocardiogram
• Echocardiogram
• X-Ray
• Myocardial Biopsy
• Chest MRI

By Treatment

• Medicine
• Antibiotics
• Anti-Inflammatory Medications
• Surgeries
• Others

Global Inflammatory Heart Disease Diagnosis and Treatment Market Report Segment by Region 

North America 

· United States 

· Canada 

Europe 

· UK 

· Germany 

· Italy 

· Spain 

· France 

· Rest of Europe 

Asia-Pacific 

· China 

· India 

· Japan 

· South Korea 

· Rest of Asia-Pacific 

Rest of the World 

· Latin America

· Middle East and Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/inflammatory-heart-disease-market